Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab \r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within days prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab; Note: influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within days prior to randomization or at any time during the study Patients must not have received of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live attenuated vaccine will be required during the study; inactivated vaccines (such as hepatitis A or polio vaccines) are permitted during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must no receive live attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day and for at least weeks after the last dose Administration of a live, attenuated vaccine within weeks before Cycle , Day or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine within weeks prior to Cycle , Day , at any time during the study or months after the last dose of atezolizumab Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study. GENERAL: Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study. Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before start of study treatment or anticipation that such a live, attenuated vaccine will be required during the study.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to start of study treatment or at any time during the study. Administration of a live, attenuated vaccine within weeks prior to initiation of study treatment with atezolizumab or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to May in the Northern Hemisphere); patients must agree not to receive live attenuated influenza vaccine (e.g., FluMist) within days prior to study treatment, during treatment, or within days following the last dose of atezolizumab Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study a) Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Patients who received a live, attenuated vaccine =< days before study treatment or are anticipated to require such a live attenuated vaccine are not eligible\r\n* NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< days prior to study registration or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle day or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); subjects must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle day or at any time during the study Administration of a live, attenuated vaccine =< weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study or for months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March)\r\n* Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to enrollment, at any time during the study, or for months after the last dose of atezolizumab Patients who received a live, attenuated vaccine =< days before study registration or are anticipated to require such a live attenuated vaccine are not eligible; NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< days prior to study registration or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Patients who have had a live, attenuated vaccine within weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks before initiation of study treatment or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study. (Influenza vaccination should be given during influenza season only [approximately October to March]. Patients must not receive live, attenuated influenza vaccine [e.g., FluMist] within weeks prior to cycle , day or at any time during the study.) Administration of a live, attenuated vaccine within days before week , day or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to week , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study and until months after the last dose of atezolizumab Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to Cycle , Day or at any time during the study. Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live attenuated vaccine will be required during the study;\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before treatment start or anticipation that such a live attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to treatment start or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to cycle , day or at any time during the study Administration of a live, attenuated vaccine within weeks before cycle , day or anticipation that such a live, attenuated vaccine will be required during the study and up to months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within weeks prior to cycle , day or at any time during the study Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within weeks prior to Cycle , Day or at any time during the study. Influenza vaccination with live attenuated vaccine in the weeks prior to randomization Subjects who have already received the seasonal influenza vaccine in the current influenza vaccination season